

Food and Drug Administration Rockville MD 20857

JUN 19 1987

Re: Buspar Docket No. 86E-0456

X/9

Charles E. Van Horn, Esq.
Director, Patent Examining Group 120
U.S. Patent and Trademark Office
Washington, DC 20231

Dear Mr. Van Horn:

This is in regard to the application for patent extension for U.S. Patent 4,182,763 filed by Mead Johnson & Company under 35 U.S.C. 156. The human drug product claimed by the patent is Buspar (buspirone hydrochloride), New Drug Application number 18-731.

In the December 17, 1986 issue of the <u>Federal Register</u>, the Food and Drug Administration published its determination of the product's regulatory review period, as required under 35 U.S.C. 156(d)(2)(A). That notice provided that on or before June 15, 1987, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. 156(d)(2)(B)(i) for a determination of whether the patent extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to the notice regarding Buspar has expired, and FDA has received no such petition. FDA, therefore, considers its determination of the regulatory review period for Buspar to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson

Director

Health Assessment Policy Staff

Office of Health Affairs

cc: Isaac Jarkovsky, Esq.
Assistant General Counsel - Patents
Bristol-Myers Company
345 Park Avenue
New York, NY 10154